Jonathan Riess, MD, MS

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Genentech
    Topic:
    Advisory Board
    Date added:
    10/15/2022
    Date updated:
    04/23/2024
    Relationship end date:
    07/01/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Blueprint
    Topic:
    Consulting
    Date added:
    10/15/2022
    Date updated:
    04/23/2024
    Relationship end date:
    03/31/2021
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Boehringer Ingelheim
    Topic:
    Consulting
    Date added:
    10/15/2022
    Date updated:
    04/23/2024
    Relationship end date:
    10/01/2021
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Regeneron
    Topic:
    Advisory Board/Consulting
    Date added:
    10/15/2022
    Date updated:
    04/23/2024
    Relationship end date:
    08/01/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Sanofi
    Topic:
    Advisory Board
    Date added:
    10/15/2022
    Date updated:
    04/23/2024
    Relationship end date:
    10/12/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Jazz Pharmaceuticals
    Topic:
    Advisory Board
    Date added:
    10/15/2022
    Date updated:
    04/23/2024
    Relationship end date:
    06/22/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Novartis
    Topic:
    Consulting
    Date added:
    10/15/2022
    Date updated:
    04/23/2024
    Relationship end date:
    08/24/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Biodesix
    Topic:
    Advisory Board
    Date added:
    10/15/2022
    Date updated:
    04/23/2024
    Relationship end date:
    08/01/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    EMD Serano
    Topic:
    Advisory Board
    Date added:
    10/15/2022
    Date updated:
    04/23/2024
    Relationship end date:
    01/27/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Boehringer Ingelheim
    Topic:
    Consulting
    Date added:
    10/15/2022
    Date updated:
    04/23/2024
    Relationship end date:
    09/21/2022

Pages

Return to San Diego Multidisciplinary Thoracic Oncology Symposium: Patient-centered approach to improve outcomes